IGF1R and neoplasm: Notably, the first clinical trial combining the anti-IGF-1R mAb, cixutumumab, with the mTOR inhibitor, temsirolimus, demonstrated tumor regression of more than 20% in approximately 29% of the patients and a sevenfold increase in median response duration (>14 months) in patients with ES (22).